Antonella Marino

P.O. S. Giuseppe Moscati, Via Gramsci
Aversa, 81031, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Fibronectin Glomerulopathy: A Case Report of Membranoproliferative Glomerulonephritis.

Fibronectin Glomerulopathy: A Case Report of Membranoproliferative Glomerulonephritis.

Journal: Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia

Published: May 17, 2026

Type I Hyperprolinemia - What about the Kidney?

Type I Hyperprolinemia - What about the Kidney?

Journal: Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia

Published: December 29, 2023

A possible relationship between anti-SARS-CoV-2 vaccination and glomerular diseases: food for thought for the nephrologist

A possible relationship between anti-SARS-CoV-2 vaccination and glomerular diseases: food for thought for the nephrologist

Journal: Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia

Published: April 26, 2022

De-escalating cancer treatments during COVID 19 pandemic: Is metronomic chemotherapy a reasonable option?

De-escalating cancer treatments during COVID 19 pandemic: Is metronomic chemotherapy a reasonable option?

Journal: Critical reviews in oncology/hematology

Published: April 22, 2020

Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer patients: safety and efficacy. An Italian experience.

Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer patients: safety and efficacy. An Italian experience.

Journal: Tumori

Published: December 19, 2019

Phase II Study of Preoperative Treatment with External Radiotherapy Plus Panitumumab in Low-Risk, Locally Advanced Rectal Cancer (RaP Study/STAR-03).

Phase II Study of Preoperative Treatment with External Radiotherapy Plus Panitumumab in Low-Risk, Locally Advanced Rectal Cancer (RaP Study/STAR-03).

Journal: The oncologist

Published: September 22, 2017

Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial.

Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial.

Journal: ESMO open

Published: June 21, 2016

Panitumumab after progression on cetuximab in KRAS wild-type metastatic colorectal cancer patients: a single institution experience.

Panitumumab after progression on cetuximab in KRAS wild-type metastatic colorectal cancer patients: a single institution experience.

Journal: Tumori

Published: April 22, 2015

BMI variation increases recurrence risk in women with early-stage breast cancer.

BMI variation increases recurrence risk in women with early-stage breast cancer.

Journal: Future oncology (London, England)

Published: December 20, 2014

Clinical outcomes and cardiac safety of continuous antiHer2 therapy in c-erbB2-positive metastatic breast cancer patients.

Clinical outcomes and cardiac safety of continuous antiHer2 therapy in c-erbB2-positive metastatic breast cancer patients.

Journal: Journal of chemotherapy (Florence, Italy)

Published: January 08, 2014

Poly (ADP-ribose) polymerase (PARP): rationale, preclinical and clinical evidences of its inhibition as breast cancer treatment.

Poly (ADP-ribose) polymerase (PARP): rationale, preclinical and clinical evidences of its inhibition as breast cancer treatment.

Journal: Expert opinion on therapeutic targets

Published: March 27, 2012

Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer: where are we now and where are we going?

Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer: where are we now and where are we going?

Journal: Critical reviews in oncology/hematology

Published: November 25, 2011

Showing 1-12 of 12

Last Updated: 09/26/2026